Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/675"
Predicate | Value (sorted: default) |
---|---|
rdfs:label | |
rdf:type | |
?:Evidence_assump_list_id |
"128"
|
?:Evidence_enzyme_system | |
?:Evidence_type | |
?:claim_assumed_valid_for_evidence_application_evidence_1663 | |
?:content |
"CYP3A Inhibitors
Do not use Ranexa with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir. Ketoconazole (200 mg twice daily) increases average steady-state plasma concentrations of ranolazine 3.2-fold"
|
dc:creator | |
dc:date |
"09/24/2009 15:51:39"
|
rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ranolazine_primary_total_clearance_enzyme_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1663 }